Celcuity
Prix: 88.55Entreprise et modèle économique
Celcuity is a healthcare company focused on developing innovative cancer therapies. Its core product is the Celcuity platform, which utilizes a proprietary technology to identify and target specific cancer cell types. The company primarily operates in the oncology segment, generating revenue through partnerships and collaborations with pharmaceutical companies for drug development and clinical trials.
Profil d’investissement
The investment profile of Celcuity is more aligned with growth investors, given its focus on developing new therapies and potential market expansion. The company does not currently offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, with moderate liquidity reflecting the stock's trading characteristics.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -3.89 Risque
- Surprise BPA
- 9.3% meilleur que prévu
- Volatilité 20 j
- 6.5% normal
Impact de la prévision
négatifSuivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-03 02:36 | Conserver | Vendre | scenario_deterioration |
| 2026-05-08 15:34 | — | Conserver | Weak fundamentals with high volatility and uncertain market signals. |
| 2026-05-05 02:37 | — | Conserver | Компания демонстрирует значительный рост цен за последние месяцы, что указывает на позитивные ожидания рынка. Однако отрицательный EPS и высокая волатильность требуют осторожности. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-03 12:48 | Craig-Hallum | Objectif abaissé | 189 → 171 | 89.1199 |
| 2026-06-03 10:07 | H.C. Wainwright | Objectif abaissé | 185 → 145 | 91.42 |
| 2026-06-03 09:28 | Wells Fargo | Objectif abaissé | — → 166 | 91.42 |
Rien pour le moment